Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
TheFly reported on May 14 that HUMA saw its price target increased at TD Cowen to $1.50 from $1.00 in a revised research update, with a Buy rating reiterated on the shares.





